KLow80 Research | QSC Metabolic Blend 80mg | 4 Pathways
QSC PROPRIETARY RESEARCH BLEND
≥99% HPLC Each ComponentMS ConfirmedJanoshik COAMetabolic Research Stack80mg Per Vial
What is KLow80?
KLow80 is a QSC proprietary metabolic research blend — 80mg total per vial. Combines semaglutide (50mg), cagrilintide (10mg), BAM15 (10mg), and 5-Amino-1MQ (10mg) to target four independent metabolic pathways simultaneously: GLP-1R agonism, amylin receptor activation, mitochondrial uncoupling, and NNMT inhibition. Exclusive QSC formula, Janoshik COA verified.
Components
Semaglutide 50mg — GLP-1R Agonist Backbone
Primary appetite suppression and insulin secretion via GLP-1R. Highest-evidence weight loss mechanism.
Cagrilintide 10mg — Amylin Analog
Area postrema activation — reduces meal size and frequency via complementary mechanism to GLP-1. Additive not redundant appetite suppression (CagriSema Phase 2 data).
BAM15 10mg — Mitochondrial Uncoupler
Proton gradient dissipation increases basal energy expenditure without hyperthermia seen with DNP. Adds thermogenesis component absent in pure appetite-suppressant approaches.
5-Amino-1MQ 10mg — NNMT Inhibitor
Raises intracellular NAD+, activates SIRT1, promotes fat oxidation. Targets hepatic fat and adipose metabolism independently of appetite pathways.
